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with a low-sodium diet. Patch clamp 
experiments on split-open CCDs of 
 animals fed a low-sodium diet for 7 days 
showed a robust stimulation of ROMK 
channel activity by angiotensin. In a pre-
vious study, Wei  et al. demonstrated that 
angiotensin II inhibits ROMK channel 
activity under conditions of a low-potas-
sium diet but not under conditions of a 
normal-potassium diet. 10 So, apparently, 
not only does a high-potassium diet sup-
press angiotensin II, but it also may make 
ROMK channels resistant to the eff ects of 
angiotensin II. However, if angiotensin 
II-induced c-Src inhibited the eff ect of SGK 
on WNK4 in the distal convoluted tubule, 
then that would result in inhibition of NCC 
function (which clearly does not happen 
with increased angiotensin II and aldoster-
one). Th erefore, this theory requires that 
c-Src is acting on the SGK1 – WNK4 inter-
action only in the CNT and CCD and not 
in the distal convoluted tubule. Th is type of 
cell-specifi c eff ect is certainly possible but 
has yet to be proven.  
 Th e authors astutely point out that these 
theories do not exclude each other, and in 
fact it is quite likely that multiple factors 
play a role in this phenomenon. Another 
potential factor to consider here is the 
temporal nature of these eff ects. In this 
study the authors looked at acute eff ects 
of angiotensin (within minutes) in both 
their animal and their cell-culture experi-
ments. Aldosterone probably upregulates 
NCC over periods of days (although 
shorter-term effects of aldosterone on 
NCC have not been studied). So it may be 
that the angiotensin II eff ect is responsible 
for acute preservation of potassium in the 
face of a low-salt diet or volume depletion 
and NCC upregulation by aldosterone is 
responsible for chronic preservation of 
potassium. It is unknown how quickly the 
diet-induced changes in WNK1 isoforms 
occur, but they could play an acute or 
chronic role. Th e example of Gitelman ’ s 
syndrome, in which patients have signifi -
cant potassium wasting despite chronic 
angiotensin II / aldosterone stimulation, 
would argue that decreased sodium deliv-
ery is the primary chronic preservation 
mechanism. Because these patients lack 
fully functional NCC, they are unable to 
increase NCC activity. Th erefore, sodium 
delivery to the CNT and CCD cannot be 
decreased, and they develop potassium 
wasting despite angiotensin. Nonetheless, 
acute preservation of potassium (less than 
72  h) is also of great import, and all of 
these pathways for potassium preserva-
tion are likely to be physiologically 
 important. 
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 Nanocrystals seed calcification 
in more ways than one 
 Diane  Proudfoot 1 and  Catherine M.  Shanahan 1 
 Although much progress has been made in the past five years in 
understanding the mechanisms leading to accelerated vascular 
calcification in patients with chronic kidney disease, it remains unclear 
how an environment high in phosphate can impinge so significantly on 
the calcification process. The study by Sage  et al. highlights an important 
and novel role for calcium phosphate nanocrystals, produced in a high-
phosphate environment, in rapidly driving calcification of vascular smooth 
muscle cells via enhanced production of bone morphogenetic protein-2. 
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 ELEVATED PHOSPHATE PROMOTES 
VASCULAR SMOOTH MUSCLE CELL 
CALCIFICATION 
 Vascular calcifi cation in patients with 
chronic kidney disease (CKD) is a prev-
alent condition that contributes to a high 
incidence of cardiovascular mortality. 
Clinical studies have demonstrated that 
elevated serum levels of phosphate (P) 
correlate with calcifi cation and mortal-
ity, and hence there have been increased 
eff orts in recent years to try and estab-
lish the mechanisms whereby elevated P 
acts to promote vascular calcifi cation. 
 Although vascular calcifi cation in CKD 
was once considered an end-stage  ‘ passive ’ 
process of precipitation of calcium phos-
phate (Ca / P) in the vessel wall, evidence 
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fi rst presented in the 1990s, showing that 
vascular smooth muscle cells (VSMCs) 
were intimately involved in the calcifi ca-
tion process, radically changed this view-
point. It is now clear that under normal 
conditions, potent inhibitors derived both 
from serum and from VSMCs actively 
suppress calcifi cation; however, in CKD, 
these inhibitors are absent or dysfunctional. 
In addition, VSMCs undergo both apoptosis 
and phenotypic change, to express 
genes normally associated with an 
osteo / chondrocytic program, at sites of cal-
cification. In combination, all these 
factors appear to be required for the 
deposition of Ca / P nanocrystals in the vessel 
wall. Th ese microscopic crystalline deposits 
eventually coalesce and progress to overt 
calcifi cation that is measurable clinically. 
 Importantly, experiments  in vitro have 
shown that high-phosphate conditions can 
promote all these essential requirements for 
calcifi cation. Detailed studies have shown 
that P uptake by VSMCs via the sodium-
dependent phosphate transporters Pit-1 and 
Pit-2 can induce Runx2 expression and pro-
mote osteogenic gene expression, while P 
can also promote VSMC apoptosis via dis-
ruption of the Axl / Gas6 pathway. 1 However, 
despite a plethora of studies addressing mul-
tiple aspects of P-induced calcification, 
results from diff erent models and systems 
have oft en provided confl icting data, casting 
doubt on the notion that uptake of P alone, 
acting via these signaling pathways, is all 
that is required to promote calcifi cation. 
 CALCIUM PHOSPHATE NANOCRYS-
TALS PROMOTE VASCULAR SMOOTH 
MUSCLE CELL OSTEOGENIC GENE 
EXPRESSION 
 Sage  et al. 2 (this issue) have now 
uncovered a novel mechanism by which 
high P in the culture medium acts to 
induce VSMC calcifi cation. Th ey showed, 
using centrifugation and electron micro-
scopic analysis, that the addition of 2  m m 
P to mouse VSMC cultures induced the 
formation of octacalcium phosphate 
nanocrystals in the extracellular medium. 
Importantly, the presence of these crystals 
led to an increased expression of the 
osteogenic proteins bone morphogenetic 
protein-2 (BMP-2) and osteopontin, pro-
teins that were not upregulated by high P 
alone. Th is was confi rmed by experiments 
showing that inhibition of crystal forma-
tion with inorganic pyrophosphate 
blocked the effects of 2  m m P on 
VSMC phenotype. 
 Th e mechanism by which these nano-
particles signal to alter gene expression is 
not yet clear; however, Sage  et al. 2 suggest 
that the nanoparticles were endocytosed. 
Endocytosis of Ca / P crystals by VSMCs 
has been shown previously, and in these 
studies, dissolution of these crystals in the 
lysosomes resulted in the release of cal-
cium ions into the cytosol and subsequent 
apoptosis. 3 Whether this calcium burst 
can also induce changes in gene expres-
sion in the cells that are able to survive, 
or whether another mechanism is respon-
sible, requires further examination. 
However, evidence from studies of related 
disease processes, in which the eff ects of 
nanocrystals on cell phenotype are well 
established, suggests that nanocrystals can 
impact on a variety of cell functions, 
including proliferation, activation of 
the mitogen-activated protein kinase sig-
naling cascade, activation of matrix 
metalloproteinases, induction of proin-
fl ammatory cytokines, 4,5 and stimulation 
of endocytotic activity. 6 Although it 
remains to be tested whether nanocrystals 
can also stimulate these activities in 
VSMCs, all of these processes are likely to 
impact on calcifi cation. Th us, the presence 
of nanocrystalline Ca / P could lead to 
a pathological positive-feedback loop 
causing more cell death, infl ammation, 
phenotypic change, matrix degradation, 
and calcifi cation ( Figure 1 ). Indeed, this 
notion is strongly supported by  in vivo 
studies by Aikawa  et al. , in which detec-
tion of nanocrystalline deposits in mouse 
atherosclerotic arteries correlated with the 
onset of osteochondrogenic gene expres-
sion, cell death, and infl ammation. 7 It is 
also consistent with evidence from an 
organ culture model of human vessel rings 
from dialysis patients, where, aft er treat-
ment with elevated Ca and P, a wave of 
apoptosis accompanied the fi rst detection 
of nanocrystals in the vessel wall. 8 
 ARE ALL NANOCRYSTALS THE SAME? 
 Th e study by Sage  et al. 2 establishes 
that nanocrystals 30 – 500  nm in dia-
meter were the active substance in the 
induction of VSMC phenotypic change. 
Previous studies have also shown that 
the size of crystals is important in 
determining their eff ects on target cells. 3,9 
Ca / P crystals in the range of 1 – 2   m or 
less in diameter were endocytosed and 
caused toxic eff ects in VSMCs and in-
duced the release of proinfl ammatory 
cytokines from macrophages, whereas 
crystals with a diameter greater than 
20   m are mostly inert. Th is is possibly 
due to lack of cellular uptake of these 
larger particles, which may be dissolved 
by alternate extracellular mechanisms 
that do not induce the same phenotypic 
eff ects as nanocrystal uptake. 10 Th is im-
plies that calcifi cation is damaging in its 
earliest stages, prior to crystal growth or 
aggregation, making this initial stage the 
most important target for prevention. Key 
questions that need to be addressed now 
are (1) how these Ca / P crystals are fi rst de-
posited in the vessel wall and (2) whether 
all types of crystals are damaging. 
 Sage  et al. 2 show that Ca / P precipitation 
in the medium occurred over time in the 
absence of inhibitors and even with  ‘ nor-
mal ’ levels of Ca and P. Th ey also show 
that Ca was required for crystal formation. 
It is plausible that in the presence of high 
circulating levels of P and Ca, and when 
inhibitors are not replete, as observed in 
CKD, nanocrystals form directly on the 
extracellular matrix, as occurred in the 
culture medium used by Sage  et al. 2 
However, there is little evidence  in vivo 
that this direct mineral precipitation 
occurs. Instead, it appears that nanocrys-
tals fi rst manifest in membrane vesicles 
that are deposited in the extracellular 
matrix by both apoptotic and secretory 
VSMCs. Importantly, these vesicles are 
loaded with calcification inhibitors, 
including the serum protein fetuin-A, 
matrix Gla protein, and osteopontin. 11 
Moreover, proteins, particularly those that 
are glycosylated, are integral components 
of the mineral deposited in the vessel 
wall. 12 Thus,  in vivo , VSMCs may be 
exposed not to naked Ca / P nanocrystals 
but to a modifi ed form of apatite. Interest-
ingly, mineral complexed with proteins in 
serum, as well as mineral extracted from 
calcifi ed arteries, has been shown to be 
less toxic to VSMCs than naked Ca / P 
crystals, and this may be due to the 
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 presence of fetuin-A. 3 Thus it will be 
important to determine whether mineral 
from the vessel wall itself can induce osteo-
genic gene expression in VSMCs, and also 
whether diff erent forms of mineral exert 
diff erent phenotypic eff ects. 
 IS ALL OSTEO / CHONDROCYTIC 
DIFFERENTIATION THE SAME? 
 Another issue that the study by Sage 
et al. 2 highlights and that requires 
further debate is the role that osteo /
 chondrocytic diff erentiation of VSMCs 
plays in promoting vascular  calcifi cation. 
Contractile VSMC
Secretory VSMC
(adaptation/repair)
Elevated P
Elevated P
MGP
fetuin-A
Runx2 (via Pit-1)
Loss of inhibitors
Apoptosis
Nanocrystals
deposited
Endocytosis of nanocrystals
BMP-2 secretion
Increased intracellular Ca2+
inflammation?
Matrix degradation?
MAPK signaling?
Osteogenic
differentiation
VSMCs
stem cells?
Aggregates: inert?
Calcification
 Figure 1  |  Model showing pathways activated in vascular smooth muscle cells in response 
to elevated phosphate. In this model, uptake of phosphate (P) via Pit-1 may act to drive vascular 
smooth muscle cell (VSMC) phenotypic change via upregulation of the key transcription factor 
Runx2. These secretory VSMCs are able to adapt to the conditions, but loss of inhibitors and cell 
death will promote nanocrystal deposition. Once this occurs, uptake of nanocrystals initiates a 
new cycle of apoptosis, inflammation, and osteogenic gene expression, with bone morphogenetic 
protein-2 (BMP-2) able to drive calcification in surrounding cells. MGP, matrix Gla protein. 
It is well established that VSMCs  in  vitro , 
and at sites of calcifi cation  in vivo , ex-
press  proteins normally associated with 
osteoblasts and chondrocytes. Indeed, 
VSMCs can express a plethora of tran-
scription factors that regulate multi-
ple developmental osteo / chondrocytic 
pathways. In rodents, particularly mice, 
where VSMCs can transdiff erentiate fully 
into chondrocytes, osteo / chondrocytic 
diff erentiation of VSMCs is likely a ma-
jor driver of this cartilaginous calcifi ca-
tion. 13 However, in the human vessel 
wall, VSMC transdiff erentiation to form 
bone and particularly cartilage tissue 
is rare, and calcifi cation is largely dys-
trophic. More over, osteo / chondrocytic 
diff erentiation of VSMCs appears to 
occur concomitantly with calcifi cation. 
It may be that in the fi rst instance, up-
regulation of expression of a subset of 
bone and cartilage proteins is an adap-
tive response aimed at protecting the 
VSMC within a procalcifi c environment. 
Th e high expression of inhibitors such as 
osteopontin and matrix Gla protein at 
sites of calcifi cation supports this argu-
ment. Subsequently, another  ‘ hit ’ such as 
nanocrystal uptake is required to further 
induce a deregulated pattern of osteo /
 chondrocytic gene expression, and this 
drives calcifi cation in surrounding cells. 
 Th is notion is supported by the study by 
Sage  et al. 2 and cautions how we interpret 
the role of osteo / chondrocytic protein 
expression by VSMCs. For example, many 
studies rely on the expression of Runx2 
and the levels of alkaline phosphatase 
(ALP) activity as indicators of osteogenic 
diff erentiation of VSMCs. It has been sur-
mised that activation of ALP by Runx2, 
and degradation of the calcifi cation inhib-
itor pyrophosphate by ALP, are necessary 
and key events in the calcifi cation process. 
However, as Sage  et al. 2 demonstrate, cal-
cifi cation can proceed in the absence of 
ALP activity; although ALP was upregu-
lated by high P, blocking its activity with 
levamisole had no eff ect on calcifi cation. 
This suggests that attention should be 
focused on alternate mechanisms that 
may initiate calcifi cation and / or osteo /
 chondrocytic diff erentiation in response 
to dysregulated mineral metabolism. One 
such possibility is the induction of apop-
tosis by nanocrystals, something not 
directly tested by Sage  et al. 2 but shown 
previously. Another, demonstrated by 
Sage  et al. , 2 is that uptake of nanocrystals 
by VSMCs selectively induced limited 
osteogenic gene expression in VSMCs that 
did not involve Runx2 — only BMP-2 and 
osteopontin. Intriguingly, osteopontin is 
an inhibitor of mineral growth, and there-
fore this is consistent with its upregulation 
being an adaptive response to limit 
mineralization. Conversely, BMP-2 is a 
procalcifi c protein. Expression of this pro-
tein by VSMCs is likely to drive osteogenic 
diff erentiation in surrounding VSMCs or 
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stem cells. Perhaps more interestingly, 
BMP-2 expression has recently been found 
to be high in senescent VSMCs. 14 Th is 
suggests that nanocrystal uptake by 
VSMCs may promote premature  ‘ ageing ’ 
of these cells, promoting expression of 
morphogens that drive calcifi cation. Th is 
is consistent with ageing being a major 
risk factor for calcifi cation and suggests 
that only a subset of dysfunctional cells 
that take up Ca / P crystals may be enough 
to cause major eff ects on the surrounding 
tissue. It is now critical that we dissect the 
factors that induce expression of key sub-
sets of osteo / chondrocytic proteins in 
VSMCs and clarify the function of these 
proteins in the context of the vessel wall 
rather than just infer their function from 
studies in bone. 
 In summary, this new study by Sage 
 et al. 2 reopens, in a timely manner, a 
number of areas for debate and critical 
experimental analysis in the field of 
vascular calcifi cation. It supports the notion 
that  ‘ calcium begets calcium ’ by aff ecting 
the phenotype of surrounding cells in its 
earliest stages. It also cautions the field 
regarding how we interpret the expression 
of osteogenic proteins by VSMCs, and a 
more critical analysis of the extent, time 
course, and functionality of these proteins 
in the vasculature is required. Finally, 
it highlights a role for nanocrystals 
themselves in promoting calcification 
and suggests we now need to improve 
our understanding of the molecular 
mechanisms leading to the initial 
deposition of Ca / P in the vessel wall. 
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 Gender aff ects the prevalence and pro-
gression of renal disease in both humans 
and animals. In a variety of renal diseases, 
women have a slower deterioration of kid-
ney function than men. Th is female  ‘ pro-
tection ’ has been shown in membranous 
glomerulopathy, polycystic kidney dis-
ease, chronic renal disease of unknown 
etiology, focal segmental glomeruloscle-
rosis, and probably IgA nephropathy. 1,2 
Whether the gender disparity in renal 
 Raging hormones: gender 
and renal disease 
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 Gender affects the progression of renal disease. In a variety of animal 
models and in certain human renal diseases, females exhibit a more 
modest course of kidney disease. Estrogens and testosterone have been 
implicated in this gender disparity. Doublier and colleagues explore the 
direct effects of sex hormones on podocyte viability in the   -estrogen 
receptor knockout (  ERKO) mouse. They report that testosterone 
induces, and estradiol inhibits, podocyte damage in this model. 
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 disease progression is related to known 
progression factors for renal disease, such 
as proteinuria, is unclear. Th ese fi ndings 
in humans are paralleled in many animal 
models of renal disease, such as aging, 
ablation, hypertension, and polycystic 
kidney disease, in which females either are 
protected from the development of 
glomerulosclerosis or have more modest 
renal disease. 3 Interestingly, in certain 
experimental models of diabetic neph-
ropathy, as well as in hyperlipidemic ani-
mal models, female sex is not protective 
and, in fact, serves as a risk factor for renal 
disease progression. 3 Diabetic renal dis-
ease progression in humans does not 
appear to have a clear sex predilection, 
although recent data suggest that renal 
